Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 116
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
This randomized phase II trial studies how well venetoclax and sequential busulfan, cladribine, and fludarabine phosphate before donor stem cell transplant work in treating patients with acute myelogenous leukemia or myelodysplastic syndrome. Giving chemotherapy before a donor peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.
详细描述
PRIMARY OBJECTIVE:
I. To compare progression free survival of two schedules of venetoclax, timed sequential busulfan, cladribine and fludarabine conditioning regimen in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
SECONDARY OBJECTIVES:
I. Compare overall survival between the two schedules. II. Compare non relapse mortality between the two schedules. III. Compare neutrophil and platelet engraftment between the two schedules. IV. Compare acute and chronic graft-versus-host disease (GVHD) between the two schedules.
V. Compare cumulative incidence of relapse between the two schedules. VI. Compare grade III/IV toxicity between the two schedules.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with biopsy-proven acute myeloid leukemia or myelodysplastic syndrome with persistent disease or in remission
- •Human leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor transplant
- •Patients age 18 to 70 years old; eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age 2-17 years may be enrolled after at least 10 adults (ages 18-70 years old) have been assessed for safety at day 30
- •Direct bilirubin < 1 mg/dl
- •Alanine aminotransferase (ALT) < 3 times upper limit of normal
- •Creatinine clearance > 50 ml/min (calculated creatinine clearance is permitted)
- •Forced expiratory volume in 1 second (FEV1) >= 50% of expected corrected for hemoglobin and/or volume
- •Forced vital capacity (FVC) >= 50% of expected corrected for hemoglobin and/or volume
- •Diffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume
- •Children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room air
- •Left ventricular ejection fraction (LVEF) >= 40%
- •Patient, legally authorized representative (LAR), or parent able to sign informed consent; able to give assent for patients age 7-17
- •Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study
- •Performance score of >= 70 by Karnofsky/Lansky or performance status (PS) 0 or 1 (Eastern Cooperative Oncology Group [ECOG] =< 1)
排除标准
- •Prior allogeneic or autologous transplantation
- •Uncontrolled infections
- •Human immunodeficiency virus (HIV) seropositivity
- •Hematopoietic cell transplantation (HCT) co-morbidity index score > 3; the principal investigator is the final arbiter of eligibility for comorbidity score > 3
- •Patients with prior coronary artery disease
研究组 & 干预措施
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Busulfan (Drug)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Laboratory Biomarker Analysis (Other)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Pharmacological Study (Other)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Venetoclax (Drug)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Peripheral Blood Stem Cell Transplantation (Procedure)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Allogeneic Hematopoietic Stem Cell Transplantation (Procedure)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Allogeneic Hematopoietic Stem Cell Transplantation (Procedure)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Laboratory Biomarker Analysis (Other)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Peripheral Blood Stem Cell Transplantation (Procedure)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Pharmacological Study (Other)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Fludarabine Phosphate (Drug)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Busulfan (Drug)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Cladribine (Drug)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Fludarabine Phosphate (Drug)
Arm I (busulfan days -13 and -12 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Venetoclax (Drug)
Arm II (busulfan days -20 and -13 before PBSCT)
PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
干预措施: Cladribine (Drug)
结局指标
主要结局
Progression free survival
时间窗: At 6 months
The method of Kaplan and Meier will be used to estimate distribution of progression free survival.
Disease free survival (DFS)
时间窗: Up to 2.5 years
Will test whether there is strong evidence that DFS differs between the two arms using a stratified log-rank test. Will use the Lan-DeMets alpha spending approach with an O'Brien-Fleming stopping boundary to compare the two arms.
次要结局
- Incidence of toxicity of these regimens(Up to 2.5 years)
- Time to platelet engraftment(Up to 2.5 years)
- Non-relapse mortality(Up to 2.5 years)
- Cumulative incidence of acute graft versus host disease (GVHD)(Up to 2.5 years)
- Time to neutrophil engraftment(Up to 2.5 years)
- Cumulative incidence of chronic GVHD(Up to 2.5 years)
- Overall survival(Up to 2.5 years)
- Cumulative incidence of relapse(Up to 2.5 years)